This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kishimoto, C. Articles by Abelmann, W. H. Search for Related Content PubMed PubMed Citation Articles by Kishimoto, C. Articles by Abelmann, W. H.

Circulation, Vol 82, 982-989, Copyright © 1990 by American Heart Association

ARTICLES

Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine Coxsackievirus B3 myocarditis

C Kishimoto, KA Thorp and WH Abelmann
Charles A. Dana Research Institute, Beth Israel Hospital, Boston, MA 02215.

To test the therapeutic efficacy of immunosuppression with cyclophosphamide (CYP) on coxsackievirus B3 (CB3) myocarditis, 2-week- old DBA/2 mice were inoculated with 3 X 10(2) plaque-forming units of CB3 virus. CYP (100 mg/kg/day s.c.) was administered daily on days 0-8 (experiment 1; group 2), days 8-21 (experiment 2; group 4), and days 21- 34 (experiment 3; group 6). Groups 1, 3, and 5 were infected control groups for each experiment. Spleen, thymus, and body weights were measured. In experiment 1, survival rate in group 2 on day 8 was low compared with group 1 (nine of 51 versus eight of 28; p = NS), and myocardial virus titers in group 2 on day 8 were higher (p less than 0.05) compared with group 1; however, cellular infiltration and myocardial necrosis in group 2 were less severe (p less than 0.05), and serum neutralizing antibody titers were decreased (p less than 0.01). In experiment 2, survival rate in group 4 on day 21 was significantly lower (six of 24 versus 12 of 16; p less than 0.01), but cellular infiltration, myocardial necrosis, and calcification in group 4 were significantly less severe, and serum neutralizing antibody titers were decreased (p less than 0.01). In experiment 3, survival rate, cardiac histopathology, and serum neutralizing antibody titers did not differ between groups 5 and 6. In experiments 1, 2, and 3, the treated groups were characterized by lower spleen-to-body-weight and thymus-to-body- weight ratios and by marked cellular depletion in spleen and thymus.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				A. Frustaci, C. Chimenti, F. Calabrese, M. Pieroni, G. Thiene, and A. Maseri Immunosuppressive Therapy for Active Lymphocytic Myocarditis: Virological and Immunologic Profile of Responders Versus Nonresponders Circulation, February 18, 2003; 107(6): 857 - 863. [Abstract] [Full Text] [PDF]

				A. Frustaci, M. Pieroni, and C. Chimenti Immunosuppressive therapy in inflammatory cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I69 - I72. [Abstract] [PDF]

				C. Kawai From Myocarditis to Cardiomyopathy: Mechanisms of Inflammation and Cell Death : Learning From the Past for the Future Circulation, March 2, 1999; 99(8): 1091 - 1100. [Abstract] [Full Text] [PDF]

				T. Kanda, J. E. Wilson McManus, R. Nagai, S. Imai, T. Suzuki, D. Yang, B. M. McManus, and I. Kobayashi Modification of Viral Myocarditis in Mice by Interleukin-6 Circ. Res., May 1, 1996; 78(5): 848 - 856. [Abstract] [Full Text]

				H. Takada, C. Kishimoto, and Y. Hiraoka Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model : Antiviral and Anti-inflammatory Effects Circulation, September 15, 1995; 92(6): 1604 - 1611. [Abstract] [Full Text]

				M. Kodama, S. Zhang, H. Hanawa, M. Saeki, T. Inomata, K. Suzuki, S. Koyama, and A. Shibata Effects of 15-Deoxyspergualin on Experimental Autoimmune Giant Cell Myocarditis of the Rat Circulation, February 15, 1995; 91(4): 1116 - 1122. [Abstract] [Full Text]